期刊文献+

角蛋白19片段K19-2G2检测在肺癌中的临床意义 被引量:2

Cytokeratin 19 Fragment K19-2G2 Detection in Lung Cancer
原文传递
导出
摘要 [目的]探讨角蛋白19片段K19-2G2检测在肺癌中的临床意义。[方法]应用化学发光免疫分析法和电化学发光法检测345例肺癌、150例肺部良性疾病和500例健康体检者(对照组)血清K19-2G2和CYFRA21-1。[结果]肺癌组患者血清K19-2G2和CYFRA21-1浓度均显著高于肺部良性疾病和对照组(P<0.01);K19-2G2检测对肺癌的灵敏性和特异性分别为61.45%和97.69%均高于CYFRA21-1(P<0.05)。K19-2G2和CYFRA21-1在非小细胞肺癌的血清浓度显著高于小细胞肺癌(P均<0.05)。早期非小细胞肺癌和进展期非小细胞肺癌血清K19-2G2浓度和阳性率相近。[结论]K19-2G2对肺癌尤其是非小细胞肺癌的具有较高的灵敏性和特异性,可能有助于非小细胞肺癌早期诊断。 [Purpose] To investigate the clinical significance of cytokeratin 19 fragment K19-2G2 detection in lung cancer.[Methods] K19-2G2 and CYFRA21-1 in 345 cases with lung cancer,150 cases with lung benign disease and 500 health volunteers(control group) were detected by chemiluminoimmunoassay and electrochemiluminescence methods.[Results] The serum content of K19-2G2 and CYFRA21-1 was significantly elevated in patients with lung cancer compared those with lung benign diseases(P0.01) or normal control group(P0.01).The sensitivity and specificity of K19-2G2 detection in lung cancer were 61.45% and 97.69% respectively,with significantly higher than those of CYFRA21-1(P0.05).The serum content of K19-2G2 and CYFRA21-1 in non-small cell lung cancer was significantly higher than those in small cell lung cancer(P0.05).The serum content and positive rate of K19-2G2 in patients with early stage non-small cell lung cancer were similar to those in advanced non-small cell lung cancer.[Conclusion] K19-2G2 is sensitive and specific to lung cancer diagnosis,especially in non-small cell lung cancer.It is helpful to diagnose for non-small cell lung cancer in early stage.
机构地区 北京军区总医院
出处 《中国肿瘤》 CAS 2011年第3期223-226,共4页 China Cancer
关键词 肺癌 角蛋白19 血清 化学发光免疫分析 lung cancer cytokeratin 19 serum chemiluminoimmunoassay
  • 相关文献

参考文献9

二级参考文献35

  • 1梁春林,张国利,陈志奇,张奇兵,梁龙彦,白山,陈克林,黄海涛.乳腺癌、胃癌及大肠癌患者外周血CK20的检测与其临床病理分期相关性研究[J].中国临床医学,2004,11(4):563-564. 被引量:6
  • 2时广利,胡秀玲,岳思东,宋长兴.血清肿瘤标志物在肺癌辅助诊断中的应用[J].中华肿瘤杂志,2005,27(5):299-301. 被引量:82
  • 3吴伟 曹江 等.肿瘤相关基因SNC90真核细胞表达型重组质粒的构建及其转化[J].生命科学研究与应用,1995,1:99-101.
  • 4[1]Barlesi F,Gimenez C,Torre J P,et al.Prognostic value of combination of Cyfra 21-1,CEA and NSE in patients with advanced non-small-cell lung cancer[J].Respir Med,2004,98(4):357-362.
  • 5[2]Stieber P,Zimmermann A,Reinmiedl J.CYFRA 21-1 in the early diagnosis of recurrent disease in non-small-cell lung carcinomas (NSCLC)[J].Anticancer Res,1999,19 (6):2665-2668.
  • 6[5]Sun S S,Hsieh J F,Tsai S C,et al.Cytokeratin fragment 19 and squamous cell carcinoma antigen for early prediction of recurrence of squamous cell lung carcinoma[J].Am J Clin Oncol,2000,23(3):241.
  • 7[6]Ardizzoni A,Cafferata M A,Tiseo M,et al.Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer[J].Cancer,2006,107 (12):2842-2849.
  • 8[7]Vollmer R T,Govindan R,Graziano S L,et al.Serum CYFRA21-1 in advanced stage non-small cell lung cancer:an early measure of response[J].Clin Cancer Res,2003,9 (5):1728-1733.
  • 9Barak V, Goike H, Panaretakis K W, et al. Clinical utility of cytokeratins as tumor markers[J]. Clin Biochem, 2004, :37 (7): 529-540.
  • 10Wu G P, Ba J, Zhao Y J, et al. Diagnostic value of CEA, CYFRA 21-1, NSE and CA 125 assay in serum and pleural effusion of patients with lung cancer[J]. Acta Cytol,2007,51 (4) :679-680.

共引文献42

同被引文献14

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部